Valneva Withdraws Chikungunya Vaccine IXCHIQ® from U.S. Market Amid FDA Scrutiny

Event summary

  • Valneva voluntarily withdrew the biologics license application (BLA) and Investigational New Drug (IND) application for IXCHIQ® in the U.S. following an FDA clinical hold due to a reported Serious Adverse Event (SAE).
  • The SAE occurred outside the U.S. and involved a younger adult who received three concomitant vaccines, including IXCHIQ®, though causality has not been determined.
  • Valneva continues to engage with health authorities in Europe, Canada, the U.K., and Brazil, where IXCHIQ® is licensed, and plans to move forward with post-marketing clinical activities.
  • Chikungunya virus is a mosquito-borne disease causing severe joint and muscle pain, with over 3.7 million cases reported in the Americas between 2013 and 2023.

The big picture

Valneva’s withdrawal of IXCHIQ® from the U.S. market highlights the regulatory risks inherent in vaccine commercialization, particularly for diseases like chikungunya with a growing global burden. The decision comes amid increasing scrutiny over vaccine safety and underscores the challenges of balancing public health needs with stringent regulatory standards. Valneva’s ability to navigate these dynamics will be critical as it continues to develop and market vaccines addressing unmet medical needs.

What we're watching

Regulatory Headwinds
How the FDA’s clinical hold will impact Valneva’s ability to regain U.S. market approval for IXCHIQ®.
Global Strategy
Whether Valneva can sustain commercialization efforts in regions where IXCHIQ® is already licensed amid heightened safety scrutiny.
Pipeline Prioritization
The pace at which Valneva shifts focus to other vaccine candidates, such as its Lyme disease and Shigella vaccines, in response to IXCHIQ®’s setbacks.

Related topics

Pharmaceuticals Biotechnology